We have Hunter corrective factor has iduronate sulfatase activity, and that evaluated the procedure for the diagnosis of the Hunter syndrome, the accumulation-correction test is an indirect way to detect a total for the detection of Hunter heterozygotes, and for the diagnosis of or near total deficiency of that enzyme (1 1, ~l t h~~~h very reliable, certain other disorders (mucolipidoses I 1 and 111 and mucopolysac-the test has not been widely adopted because it requires highly charidosis I ).
purified factor and specialized techniques. Direct measurement of
Hunter patients had 1-270 normal iduronate sulfatase activity iduronate sul,-atase activity by use of a [ 3 5~1~~~~~~l~ i n the three sources tested. The serum assay is undoubtedly the substrate (1) is prone to error and is not recommended for method o f choice to establish the diagnosis o f the Hunter syndrome.
diagnosis, on the other hand, the assay described by ~i~ (10) Less than 1 m l serum and 3-4 days are required to complete the is simple and reliable, and has now been adapted for use with procedure.
serum, lymphocytes, and fibroblasts.
Serum could not be used for the detection o f iduronidase
The principle of the assay is shown in ~i~~~~
The substrate is a deficiency diseases, but these could easily be recognized i n lymradioactive disulfated disaccharide of a sulfated iduphocyte and fibroblast preparations.
ronic acid glycosidically linked to a sulfated anhydromannitol The iduronate sulfatase activity of sera from patients with which has been labeled with tritium, [duronate sulfalase cleaves mucolipidoses 11 and 111 was elevated 20-fold, but their parents had the sulfate group from the iduronic acid residue, leaving a radioa level of this enzyme. In of patients with active monosu\fated disaccharide (produrl I ) , which in turn serves mucolipidoses I 1 and 111, both iduronate sulfatase and iduronidase as substrate for any cu-L-iduronidase that might be present, ~h~ activities were markedly decreased.
iduronidase liberates radioactive anhydromannitol sulfate @rod-Serum assays were not informative about the Hunter heterozyu,l 2) and unlabeled iduronic acid. ~~d i~~~~ products are gote status. However, the mean activity in lymphocytes from separated e~ectrophoretically from each other and from residual mothers of Hunter patients was about half o f the mean normal substrate, and are by count,ng. 
SUBSTRATE
The preparation of the substrate by deaminative cleavage of The primary defect in the Hunter syndrome (mucopolysac-heparin followed by isolation and reduction of the resulting charidosis 11) is a profound deficiency of iduronate sulfatase ( I , 5. disulfated disaccharide with NaB3H, have been previously de-16) . The stepwise degradation of derrnatan sulfate and of heparan scribed (10) . 3H-Labeled and unlabeled substrate were mixed to sulfate is interrupted at the sulfated iduronic acid residue, leading give a specific activity of 14 pCi/prnol. to massive accumulation of these polymers within lysosomes of most tissues: this cellular storage is presumed to be the cause of the PREPARATION OF BIOLOGIC SAMPLES numerous and well known clinical problems (12) . I n contrast to other mucopolysaccharidoses, which are inherited in autosomal Serum samples prepared from 2 ml blood were dialyzed against recessive fashion. the Hunter syndrome is X-linked. Correct five baths, 6 liters each. of 0.9%) NaCI. over a period of 70 hr at 4". diagnosis of this disease is obviously essential for counseling of N o activity is detected in undialyzed serum. Protein content was Hunter families.
determined after dialysis ( I I A substrate blank, containing all reagents but without the biologic sample, was incubated along with the experimental HO samples.
1
At the end of the incubation, products and residual substrate OSO;
were separated from each other by electrophoresis at approxi-SO; IDURONATE SULFATASE mately 25 V/cm and 275 ma for I hr in 1.9 M formic acid, pH 1.7, in a high voltage electrophorator model D (22) . Whatman no.
PRODUCT 1 3 M M paper, 70 by 46 cm, was soaked in the formic acid and blotted, and 25 p i incubation mixture and substrate blank were applied in 2-cm spots. A routine marker solution, consisting of substrate and product I prepared with purified iduronate sulfatase (lo), was rur. concurrently. The location of product 2 was determined in preliminary experiments by near coincidence with galactose-6-sulfate (23). a compound of identical charge and only slightly grelter molecular weight. The separation procedure differs from the one previously described (10) in that electrophoresis is performed at higher OH amperape and on Whatman no. 3MM paper. This was found 6-sulfate, is schematically depicted with an un-ionized carboxyl group of uronic acid, although at the pH of incubations this residue is predominantly in the uronate form.
and platelets) were separated over a Hypaque-Ficoll cushion (2) from 15-1111 samples of blood collected in EDTA. Ficoll 400 was obtained from Pharmacia (17) . and Hypaque (50% sodium diazotrizoate) from Winthrop Laboratores (18). The cell layer above the Hypaque-Ficoll was removed with a Pasteur pipette and washed three times with centrifugation in 0.9% NaCI. The cell pellet was taken up in 0.4 ml 0.9% NaCl and disrupted by six cycles of freeze-thawing and a final homogenization by hand in a small homogenizer (19) . The resulting homogenates were dialyzed as above, resuspended in the homogenizer, and analyzed for protein as above.
Fibroblast cultures were initiated from skin biopsies obtained in the course of diagnostic procedures. or were obtained from the Human Genetic Mutant Cell Repository (20); they were maintained as previously described (4) . The cells in 75cm2 Falcon flasks were harvested 3-4 weeks after transplantation and converted t o an acetone powder as described by Hall et al. (7) . except that 5 ml acetone were used for the cell pellet from one flask. Before use, the powders were suspended in 0.9% NaCI, (0.3 ml/original flask), stirred occasionally during 1 hr at 0°, and clarified by centrifugation at 10,000 x g for 10 min. The supernatant solutions were dialyzed as above and the protein was determined as above. Cultured amniotic fluid cells were handled in the same manner as cultured fibroblasts, except that they were used as soon as confluent. Informed consent was obtained before taking samples of blood or skin biopsies.
E N Z Y M E A S S A Y S
Assay conditions varied slightly for serum, lymphocytes, and fibroblasts. For convenience, a substrate mixture was prepared containing 0.27 M sodium acetate buffer at pH 4.0 or 4.5, 13.3 m M sodium azide. and 0.75 m M substrate. The mixture at pH 4.0 contained. in addition, I mg/ml bovine serum albumin.
Serum samples. 50 pl. were incubated with 30 pI pH 4.5 substrate mixture in capped I-ml polystyrene disposable test tubes (21) for 6 hr at 37". It is important to use equipment which minimizes evaporation from the incubation mixture.
Lymphocyte homogenntes. 50 p1 containing I00 200 pg protein, were mixed with 30 p1 pH 4.0 substrate mixture and incubated as described for serum but for 24 hr. essential to prevent artifacts caused by the'high protein content of the biologic samples, particularly of serum. Under conditions of electrophoresis or chromatography previously recommended, the substrate and products bind to the protein in variable fashion, leading to erratic results.
After drying, the paper was cut into 4-cm wide strips; the radioactive areas were located with a chromatogra~h scanner. cut -.
out, and counted at 4% efficiency in a liquid scintillation spectrometer as described (10, 24) . (10) . Under these conditions, the amount of substrate hydrolyzed per unit time is far from the maximum that would be observed under saturating conditions. The advantage of using the low substrate concentration is that the yield of products is relatively high. Optimal conditions include a combination of substrate concentration, time, and enzyme level such that 0.1-0.5 of the substrate is converted to products; below one-tenth, the blank correction becomes substantial and above 0.5, there is a marked deviation from linearity (10) . The ratio of the second product to total product formation is a rough measure of iduronidase activity. Since the iduronidase reaction is dependent on prior formation of the first product. iduronidase activity is underestimated when iduronate sulfatase is limiting, and cannot be measured at all when iduronate sulfatase is absent. The p H of the reaction mixtures is optimal for iduronate sulfatase, but higher than the optimum for iduronidase.
Characteristic zlectrophoretic patterns of residual substrate and products found at the end of incubation are shown in Figure 2 .
RESULTS
The activities of iduronate sulfatase and of iduronidase of individuals of various genotypes are reported in Table 1 . A number of conclusions emerge from the data.
On the basis of protein content, normal fibroblast extracts have 5 times the iduronate sulfatase activity of normal lymphocyte homogenates. which in turn have 4 times the activity of serum. However, the amount of serum used per assay corresponds to 0. I ml blood, whereas the lymphocyte homogenate is derived from 0.5-2 ml.
Hunter patients had about 1 2 % of normal activity in the three sources tested. It is not known whether this represents true residual activity of a defective iduronate sulfatase or the action of some other, nonspecific sulfatase. As with previous tests ( I , 3) . there was * Limit of detection = 0.02. no greater activity in patients with the mild form than in those with the severe form (12) of the disease.
Serum could not be used for the detection of iduronidase deficiency diseases (i.e., mucopolysaccharidosis I-the Hurler, Scheie, and Hurler/Scheie syndromes) since iduronidase activity could not be detected in normal serum by the present assay. However, lymphocyte and fibroblast preparations from mucopolysaccharidosis I patients could easily be recognized by the absence of the second product. In spite of the imprecise nature of the iduronidase determination, lymphocytes from Hurler heterozygotes were found to have reduced activity. The iduronate sulfatase activity of sera from patients with mucolipidoses I I (I-cell disease) and I I I (pseudo-Hurlerpolydystrophy) was greatly elevated (20-fold), a s are many other lysosoma1 enzymes (see review, Reference 15). In those patients serum iduronidase was also increased, since it was clearly detectable when undiluted serum was used, although not when the serum was appropriately diluted to keep iduronate sulfatase activity within linear range. In fibroblasts, both iduronate sulfatase and iduronidase activities of patients with mucolipidoses I1 and 111 were markedly decreased, again in keeping with a number of other lysosomal enzymes (15) . However, there was only partial reduction of either enzyme in lymphocytes of the same patients. Mucolipidoses I1 and 111 heterozygotes had a normal level of iduronate sulfatase activity in serum.
Patients with mucopolysaccharidoses because of a deficiency of other enzymes had normal iduronate sulfatase and iduronidase activities.
Serum assays were not informative about the Hunter heterozygote status, since the mean activity of sera from seven Hunter mothers (including one who had more than one affected child) was indistinguishable from the normal mean. Fibroblasts from heterozygotes were not studied extensively because of their tendency t o self-clone in culture. However, the mean activity in lymphocytes from mothers of Hunter patients was about half of the mean normal activity.
This observation is examined in greater detail in Figure 3 .
Values obtained for mothers of Hunter patients with only one affected child are separated from values obtained for mothers with two affected children or with a family history. Only the latter are considered obligate heterozygotes. since the former might include cases of sporadic mutations. A number of heterozy_eotes had iduronate sulfatase so low that they were identifiable as carriers by the enzyme test; others, unfortunately. had a clearly normal level, Fig. 3 . lduronate sulfatase activity in normal individuals and in Hunter heterozygotes.
LIEBAERS AND NEUFELD
and one obligate heterozygote even had a markedly elevated level. (So did a few normal subjects. The cause of the elevated levels is not known: it is probably not the result of polymorphism, but rather of a transient problem, since the normal individual who had the highest level when first tested had normal activity when lymphocytes were prepared 6 months later). The possible heterozygote status of the Hunter mother with the lowest enzyme activity, plotted in Figure 3 , was confirmed by cloning her fibroblasts and finding both normal and Hunter clones (13) .
A few close female relatives (sisters and aunts) of Hunter patients were also tested; two of these had activity so low that they h a y be presumed to be heterozygotes.
DISCUSSION
The serum assay is undoubtedly the method of choice to establish the diagnosis of the Hunter syndrome. Less than I ml serum is required; the enzyme is stable in the frozen state for years, so that a diagnosis may be established retrospectively for deceased patients. Plasma may also be used, although in that case the normal values may differ somewhat from those reported in Table  1 . The time required for a biochemical diagnosis is 3-4 days when serum is used, instead of the 4-6 weeks needed if fibroblasts cultures are to be established. This reduction in waiting time is particularly valuable when the biochemical diagnosis of the patient is requested in conjunction with a prenatal diagnosis for a close relative.
The assay was originally developed for use with extracts of fibroblasts; however, we found it more laborious than the [35S]mucopolysaccharide accumulation and correction procedure, primarily because of the preparation of acetone powders. Nevertheless, it is of interest that cultured fibroblasts and amniotic fluid cells have a high level of enzyme activity. We have used the presence of iduronate sulfatase activity in cultured amniotic fluid cells as confirmation of normal results obtained by other methods. Further experience is needed to determine the reliability of the enzyme assay for prenatal diagnosis.
Detection of iduronidase deficiency diseases by the present assay is possible, but presents no obvious advantages over established procedures (8) except in those occasional instances where the information is obtained in the course of testing for the Hunter syndrome.
The possibility of carrier detection by the lymphocytes assay needs further development. It is clear that at the present time. half of the obligate heterozygotes have enzyme activity well within the normal range. This number may be reduced by technical improvements. However, certain genetically heterozygous women may remain undetectable by biochemical tests. This would occur if some selective advantage in favor of their cells with an active paternal X-chromosome has left them with predominantly normal somatic cells, rather than the mixture of normal and Hunter cells predicted by the Lyon hypothesis (6, 13).
SUMMARY
Profound deficiency of iduronate sulfatase activity is found in serum. lymphocytes. and fibroblasts of Hunter patients by a new assay procedure. Serum samples are especially u~eful for diagnostic purposes. The assay also reveals a marked increase of iduronate sulfatase in the serum. and a deficiency in the fibroblasts, of patients with mucolipidoses I I or Ill. The same assay detects a-L-iduronidase activity (and the corresponding deficiency state) in normal lymphocytes and fibroblasts, although not in serum. Lymphocytes of Hunter heterozygotes have half of normal activity on a statistical basis, but the scatter is so great that only half the obligate heterozygotes can presently be identified by the test.
